Home
overview

16th to 17th February 2009, Crowne Plaza Hotel - St James, London, United Kingdom.

The development of stem cells for therapeutic purposes, including cell therapy and regenerative medicine, is emerging as a major field of pharmaceutical research. Stem-cell technology is also making inroads in drug discovery. This technology offers great potential for understanding disease mechanisms and identifying targets, and for effective toxicology screening.

This conference addresses both therapeutic and non-therapeutic stem-cell applications. For companies engaged in cell-therapeutics, the technical aspects of achieving stable stem cell populations, as well as product manufacturing challenges and logistics are addressed.  Large pharma are increasingly turning to stem cells to identify targets for drug development and for toxicology testing.  Also, they are looking to partner with smaller biotech firms to develop commercially viable regenerative medicine products.  Networking and presentations by both will foster this relationship.

Experts in stem cell science and applications, as well as policy and bio-business come together to cover the emerging role of stem cells in drug development and therapy.   As stem cell science matures, it becomes clear that supply and technology will soon cease to limit product development, and that pharmaceutical companies engaged with stem cells will have a competitive advantage.  For those who share this attitude, this is a must-attend event.

Critical challenges that will be addressed:
  • UNDERSTAND new processes in stem cell differentiation and expansion
  • EVALUATE stem cell applications for drug discovery and predictive toxicology
  • FORECAST applicabililty of stem cell technologies for therapeutic potential
  • ASSESS commercial viability of cell-based products
  • INVESTIGATE strategic partnerships between biotech and pharmaceutical industries
  • UNDERSTAND the latest developments in the IP and regulatory landscape
Vice Presidents, Directors and Group Leaders from within the biotech or pharmaceutical industry with responsibilities in the following areas:
 
  • Drug Discovery
  • Target Identification/Validation
  • Regenerative Medicine
  • Tissue Engineering
  • Disease Biology and Profiling
  • Toxicology
  • Cancer Stem Cells
  • Biopharmaceuticals
  • Cell Transplantation
  • Drug Design
  • Bioinnovation
  • Strategic Partnerships
  • Stem Cell Therapy
  • ATMP Regulation 
  • Alliance Management
 
 
 
 

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Tim Allsopp

Tim Allsopp, Chief Scientific Officer, Stem Cell Sciences

9:10 KEYNOTE SESSION: HUMAN EMBRYONIC STEM CELL THERAPIES

Tom Okarma

Tom Okarma, Chief Executive Officer, Geron

  • Geron Corporation will be the first to bring human embryonic stem cell therapies to the clinic
  • Content of Geron’s GRNOPC1 IND
  • The application to the FDA seeking permission to study hESC-derived oligodendroglial progenitor cells in patients with subacute spinal cord injury
  • 9:45 HOW TO BOOST STEM CELL NUMBERS IN THE BLOOD

    Sara Rankin

    Sara Rankin, Reader in Leukocyte and Stem Cell Biology, National Heart & Lung Institute, Imperial College

  • For many years haematologists have used G-CSF to mobilize haematopoietic stem cells (HPCs) from bone marrow
  • Recently the CXCR4 antagonist Mozobil has been shown to mobilize HPCs, acting synergistically with G-CSF
  • We show that other distinct populations of bone marrow stem cells, endothelial progenitors and mesenchymal stem cells that promote tissue repair are mobilized by a combination of VEGF and Mozobil. This drug therapy does not mobilize HPCs
  • The molecular mechanisms underlying the differential mobilization of these stem cell populations will be discussed
  • 10:20 STANDARDIZATION OF STEM CELL CULTURING

    Judit Nagy

    Judit Nagy, Research Scientist, Director Proteomics Facility, Imperial College

  • Serum free culture media
  • Starting material
  • Reproducible end product
  • 10:55 Morning Coffee

    11:25 STEM CELL BASED SYSTEMS IN REPRODUCTIVE TOXICOLOGY

    Karim Nayernia

    Karim Nayernia, Chair of Stem Cell Biology, North East England Stem Cell Institute

  • ESCs as an innovative alternative for early efficacy and reproductive toxicity screening
  • Advantages and limitations of this system
  • Combining stem cell technology and microarray techniques to understand reproductive toxicants
  • 12:00 STEM CELLS FOR REGENERATIVE MEDICINE; SCALABLE PLATFORM TECHNOLOGIES

    Thorsten Gorba

    Thorsten Gorba, Research Team Leader, Stem Cell Sciences

  • Why robust scaling is important
  • Stem cell based assays and screens
  • Can tissues be regenerated or reprogrammed from within?
  • 12:35 A HIGH CONTENT ANALYSIS APPROACH TO STEM CELL RESEARCH

    Neil Durso

    Neil Durso, Field Application Scientist, Thermo Scientific Cellomics High Content Analysis Technologies, Thermo Fisher Scientific

  • High Content Analysis (HCA) is an emergent technology that is now established in many different areas of research
  • The capacity of HCA to make multiple quantitative cell-by-cell measurements coupled with the ability to specifically define targeted cellular populations makes it a powerful tool for understanding the signaling processes, differentiation and physiology of stem cells
  • A High Content approach can lead to greater productivity and accelerated research in this key biological area
  • 13:15 Networking Lunch

    14:15 KEYNOTE SESSION: REPROGRAMMING iPS CELLS

    Sir Ian Wilmut

    Sir Ian Wilmut, Director, Scottish Centre for Regenerative Medicine

  • Derivation successes and selection strategies
  • Comparing properties of iPS with ESCs
  • Applying iPS technology to unmodified cells
  • Application of iPS technology in disease therapies
  • 14:50 STEM CELLS IN TRANSLATIONAL MEDICINE

    Rajesh Chopra

    Rajesh Chopra, Global Medical Science Director and Senior Principal Scientist, AstraZeneca

  • Pharma's perspective on therapeutic products from stem cells
  • Business development potential
  • Combination products
  • 15:25 STEM CELLS IN PREDICTIVE TOXICOLOGY

    Louise Leong

    Louise Leong, Science Director, SC4SM, Stem Cells for Safer Medicine

  • SC4SM - A public private partnership
  • Drivers in drug safety evaluation
  • Research programme and future direction
  • 16:00 Afternoon Tea

    16:30 EMBRYONIC STEM CELL-DERIVED NEURONS AS A CELLULAR MODEL FOR DRUG DISCOVERY

    Miriam Bibel

    Miriam Bibel, Senior Research Investigator, Novartis

  • Technological advances in neuronal differentiation methods
  • Target identification and validation
  • Pharmacological screening
  • 17:05 CANCER STEM CELLS

    Dominique Bonnet

    Dominique Bonnet, Senior Group Leader, Cancer Research UK

  • Identification
  • Characterisation
  • New therapeutic targets
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Diane Harbison

    Diane Harbison, Associate Director, Pfizer Global Research and Development

    9:10 PARTNERING WITH BIOTECH

    Esteban Pombo Villar

    Esteban Pombo Villar, Head of Strategic Alliances, Novartis Institute of Biomedical Research

  • Opportunities
  • Evaluating and mitigating risk
  • New R&D paradigms
  • Licensing
  • 9:45 EVALUATING EMERGING TECHNOLOGIES

    Alain Vertes

    Alain Vertes, Global Alliance Director, Roche Pharmaceuticals

  • Cultural fit with pharmas
  • Strategic vision
  • Implementation

  • 10:20 Morning Coffee

    10:40 MAKING YOUR NEW PARTNERSHIP WORK

    Rob Hockney

    Rob Hockney, Chief Executive, Partnering Excellence

    • Identify some of the challenges you’ll need to overcome if you’re to realise the greatest possible value from your new partnership.
    • Avoiding the pitfalls that can corrode partnerships
    • Tools and approaches which help maximise the success
    • The importance of a "collaborative mindset"

    11:15 HOW TO COMMERCIALISE CELL THERAPY

  • Is the cell therapy business viable - global examples and case studies
  • How to commercialise a cell therapy product
  • The emerging cell therapy markets and opportunities
  • Elizabeth Hill

    Elizabeth Hill, Director, Head of Transactions, Cambridge Consultants

    Gabriel Markson

    Gabriel Markson, Lead Analyst Cell Therapy, Cambridge Consultants Ltd

    11:55 DEVELOPING REGENERATIVE MEDICINE IN PHARMA

    Diane Harbison

    Diane Harbison, Associate Director, Pfizer Global Research and Development

  • Pfizer’s approach to an integrated regenerative medicine unit
  • Utilizing existing collaborations
  • Resource management
  • 12:30 Networking Lunch

    13:30 PROSPECTS IN CELL TRANSPLANTATION: TREATING DIABETES

    Ole Madsen

    Ole Madsen, Director of Research, Novo Nordisk

  • molecular processes controlling pancreas ontogeny
  • ex vivo/in vivo expansion of a functional ß-cell mass
  • transplant treatment of insulin-dependent diabetes mellitus
  • 14:05 PATENTABILITY OF STEM CELLS IN EUROPE

    Aliki Nichogiannopoulou

    Aliki Nichogiannopoulou, Principle Examiner Biotechnology / Patent Law, European Patent Office

  • Awaiting speaker bullet points
  • 14:40 INVESTING IN STEM CELL TECHNOLOGY

    Cathy Prescott

    Cathy Prescott, Director, Biolatris

  • The three major business models that encompass the regenerative medicine sector
  • Typical funding levels required and potential sources of funding
  • Challenges and opportunities faced by each company-type in the context of pharma industry trends and current venture investment
  • 15:15 Afternoon Tea

    15:35 STEM CELLS FOR DRUG SCREENING AND TOXICITY TESTING

    Chikafumi Yokoyama

    Chikafumi Yokoyama, CEO, ReproCELL

  • QT prolongation by using ES-derived beating cardiomyocyte
  • ES-derived disease model cells
  • Japanese National Project of human ES cells
  • 16:10 THE REGULATION OF STEM CELL PRODUCTS

    Julian Hitchcock

    Julian Hitchcock, Senior Solicitor Life Sciences, Mills & Reeve Solicitors

  • The changing patent landscape in stem cells
  • The ATMP regulation
  • Regulation of manufacture
  • 16:45 IDENTIFYING THE STEM CELL NICHE AND TRACING CELL LINEAGES IN HUMAN TISSUES

    Malcolm Alison

    Malcolm Alison, Professor of Stem Cell Biology, Barts & The London

  • Clonal populations of cells can be identified by identical defects in the mtDNA gene encoding cytochrome c oxidase
  • Stem cell niches have been identified at the base of colonic crypts, in the periportal area of the liver and in the pancreatic ducts
  • The origin of a common skin cancer, basal cell carcinoma, has been traced to the outer root sheath of the hair follicle
  • 17:20 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Practical considerations for stem cell based predictive assays
    Workshop

    Practical considerations for stem cell based predictive assays

    Crowne Plaza Hotel - St James
    18th February 2009
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.